Positive Effects of Methylphenidate on Inattention and Hyperactivity in Pervasive Developmental Disorders: An Analysis of Secondary Measures

Biological Psychiatry

Volumn 61, Issue 4, 2007, Pages 538-544

  Posey, David J ^a   Aman, Michael G ^b   McCracken, James T ^c   Scahill, Lawrence ^d   Tierney, Elaine ^e   Arnold, L Eugene ^b   Vitiello, Benedetto ^f   Chuang, Shirley Z ^g   Davies, Mark ^g   Ramadan, Yaser ^b   Witwer, Andrea N ^b   Swiezy, Naomi B ^a   Cronin, Pegeen ^c   Shah, Bhavik ^c   Carroll, Deirdre H ^d   Young, Christopher ^d   Wheeler, Courtney ^e   McDougle, Christopher J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^g Columbia University ^*  (United States)

Author keywords

Asperger's disorder; autism; hyperactivity; inattention; methylphenidate; pervasive developmental disorder; stimulants

Indexed keywords

METHYLPHENIDATE; PLACEBO;

ADOLESCENT; ARTICLE; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; AUTISM; BEHAVIOR DISORDER; CHILD; COMPULSION; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERACTIVITY; IMPULSIVENESS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPPOSITIONAL DEFIANT DISORDER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; RATING SCALE; STEREOTYPY; SYMPTOM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CHILD, PRESCHOOL; CROSS-OVER STUDIES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES;

EID: 33846643952     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2006.09.028     Document Type: Article

References (35)

1. Aman M.G. Stimulant drug effects in developmental disorders and hyperactivity: Toward a resolution of disparate findings. J Autism Dev Disord 12 (1982) 385-398
2. Aman M.G., Lam K.S., and Van Bourgondien M.E. Medication patterns in patients with autism: Temporal, regional, and demographic influences. J Child Adolesc Psychopharmacol 15 (2005) 116-126
3. Aman M.G., Singh N.N., Stewart A.W., and Field C.J. The Aberrant Behavior Checklist: A behavior rating scale of the assessment of treatment effects. Am J Ment Defic 89 (1985) 485-491
4. Aman M.G., Singh N.N., Stewart A.W., and Field C.J. Psychometric characteristics of the Aberrant Behavior Checklist. Am J Ment Defic 89 (1985) 492-502
5. American Psychiatric Association. The Diagnostic and Statistical Manual of Mental Disorders. 4th ed. (1994), American Psychiatric Press, Washington, DC
6. Borcherding B.G., Keysor C.S., Rapoport J.L., Elia J., and Amass J. Motor/vocal tics and compulsive behaviors on stimulant drugs: Is there a common vulnerability?. Psychiatry Res 33 (1990) 83-94
7. Campbell M., Fish B., David R., Shapiro T., Collins P., and Koh C. Response to triiodothyronine and dextroamphetamine: A study of preschool schizophrenic children. J Autism Child Schizophr 2 (1972) 343-358
8. Campbell M., Small A., Collins P., Friedman E., David R., and Genieser N. Levodopa and levoamphetamine: A crossover study in young schizophrenic children. Curr Ther Res Clin Exp 19 (1976) 70-86
9. Chakrabarti S., and Fombonne E. Pervasive developmental disorders in preschool children: Confirmation of high prevalence. Am J Psychiatry 162 (2005) 1133-1141
10. Fog R. Stereotyped and non-stereotyped behavior in rats induced by various stimulant drugs. Psychopharmacologia 14 (1969) 299-304
11. Frazier J.A., Biederman J., Bellordre C.A., Garfield S.B., Geller D.A., Coffey B.J., and Faraone S.V. Should the diagnosis of attention deficit/hyperactivity disorder be considered in children with pervasive developmental disorder?. J Atten Disord 4 (2001) 203-211
12. Goldstein S., and Schwebach A.J. The comorbidity of pervasive developmental disorder and attention deficit hyperactivity disorder: Results of a retrospective chart review. J Autism Dev Disord 34 (2004) 329-339
13. Guy W. ECDEU Assessment Manual of Psychopharmacology (1976), National Institute of Mental Health, Washington, DC
14. Handen B.L., Johnson C.R., and Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 30 (2000) 245-255
15. Hollander E., Phillips A., Chaplin W., Zagursky K., Novotny S., Wasserman S., and Iyengar R. A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 30 (2005) 582-589
16. King B.H., Wright D.M., Handen B.L., Sikich L., Zimmerman A.W., McMahon W., et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 40 (2001) 658-665
17. Lecavalier L. Behavioral and emotional problems in young people with pervasive developmental disorders: Relative prevalence, effects of subject characteristics, and empirical classification. J Autism Dev Disord 36 (2006) 1101-1114
18. Lord C., Rutter M., and Le Couteur A. Autism Diagnostic Interview-Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24 (1994) 659-686
19. McDougle C.J., Holmes J.P., Carlson D.C., Pelton G.H., Cohen D.J., and Price L.H. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry 55 (1998) 633-641
20. McDougle C.J., Naylor S.T., Cohen D.J., Volkmar F.R., Heninger G.R., and Price L.H. A double-blind, placebo controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53 (1996) 1001-1008
21. McDougle C.J., and Posey D.J. Autistic and other pervasive developmental disorders. In: Martin A., Scahill L., Charney D., and Leckman J.F. (Eds). Pediatric Psychopharmacology: Principles and Practice (2003), Oxford University Press, New York, NY 563-579
22. McDougle C.J., Scahill L., Aman M.G., McCracken J.T., Tierney E., Davies M., et al. Risperidone for the core symptom domains of autism: Results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. Am J Psychiatry 162 (2005) 1142-1148
23. MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 56 (1999) 1073-1086
24. Owley T., Owley S., Leventhal B., and Cook Jr. E.H. Case series: Adderall augmentation of serotonin reuptake inhibitors in childhood-onset obsessive compulsive disorder. J Child Adolesc Psychopharmacol 12 (2002) 165-171
25. Pelham W.E., Gnagy E.M., Greenslade K.E., and Milich R. Teacher ratings of DSM-III-R symptoms for the disruptive behavior disorders. J Am Acad Child Adolesc Psychiatry 31 (1992) 210-218
26. Posey D.J., Wiegand R.E., Wilkerson J., Maynard M., Stigler K.A., and McDougle C.J. Open-label atomoxetine for attention-deficit/hyperactivity disorder symptoms associated with high-functioning pervasive developmental disorders. J Child Adolesc Psychopharmacol 16 (2006) 599-610
27. Quintana H., Birmaher B., Stedge D., Lennon S., Freed J., Bridge J., and Greenhill L. Use of methylphenidate in treatment of children with autistic disorder. J Autism Dev Disord 25 (1995) 283-295
28. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med 347 (2002) 314-321
29. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 62 (2005) 1266-1274
30. Roffman J.L., and Raskin L.A. Stereotyped behavior: Effects of d-amphetamine and methylphenidate in the young rat. Pharmacol Biochem Behav 58 (1997) 1095-1102
31. Scahill L., Aman M.G., McDougle C.J., McCracken J.T., Tierney E., Dziura J., et al. A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 16 (2006) 589-598
32. Scahill L., McDougle C.J., Williams S.K., Dimitropoulos A., Aman M.G., McCracken J., et al. The Children's Yale-Brown Obsessive Compulsive Scale modified for pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 45 (2006) 1114-1123
33. Scahill L., Riddle M.A., McSwiggin-Hardin M., Ort S.I., King R.A., Goodman W.K., et al. Children's Yale-Brown Obsessive Compulsive Scale: Reliability and validity. J Am Acad Child Adolesc Psychiatry 36 (1997) 844-852
34. Stigler K.A., Desmond L.A., Posey D.J., Wiegand R.E., and McDougle C.J. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J Child Adolesc Psychopharmacol 14 (2004) 49-56
35. Swanson J.M. School-Based Assessments and Interventions for ADD Students (1992), KC Publishing, Irvine, CA